Company Website: https://neursantys.com/
About the Demo:
1) Neursantys’ NEURVESTA wearable bioelectronic solution is an innovative platform that integrates both diagnostic sensing and therapeutic treatment for degraded sensory and motor balance functions in older adults. The NEURVESTA treatment protocol includes both a pre- and post-treatment diagnostic assessment using a novel wearable neurophysiological impairment sensing technology called physiological vibration acceleration (Phybrata) that quantifies each patient’s unique balance impairment profile. The subsequent therapeutic treatment utilizes a specialized form of non-invasive transcranial electric stimulation developed by Neursantys, called sub-threshold wideband stochastic Electrical Vestibular Stimulation (swsEVS), that has been shown to induce persistent neuroplastic recovery of degraded balance in patients between 50 and 95 years of age. The current NEURVESTA platform utilizes the same fixed swsEVS parameters for all patients, and treatment consists of three 20-minute sessions per week over a 6-week period. In collaboration with MassAITC, Neursantys is also developing ML-driven methods to adapt swsEVS parameters to each patient’s unique sensory and motor impairment profile and recovery trajectory to further enhance patient outcomes.
2) Attendees will be able to undergo a 2-minute balance assessment using the Phybrata wearable sensor (attached behind the ear with a small disposable adhesive) to quantify their overall balance performance, any impairments to sensory inputs (visual, vestibular, proprioceptive) or central nervous system balance control, and level of fall risk.
Select attendee volunteers may also undergo a single 20-minute NEURVESTA swsEVS treatment session to illustrate the postural control enhancements that are typically observed even after a single treatment session.
3) Declining balance and mobility, clinically referred to as presbystasis, is one of the most visible, debilitating, and costly signs of aging. Presbystasis significantly degrades overall health, increases the risk of falls, and hinders the ability to live actively, independently, and productively. Although presbystasis is a multifaceted disorder, studies of balance aging have identified age-related changes in the vestibular balance organs in the inner ear, clinically known as presbyvestibulopathy, as the primary cause of balance decline in more than 55% of all adults over the age of 50 (70 million older Americans). But despite an economic impact exceeding $280 billion each year in the U.S. alone, there is still no widely available solution to restore this aging vestibular balance function. Neursantys has solved this problem by developing an easy-to-use wearable device, NEURVESTA, that delivers a unique form of safe and gentle non-invasive bioelectronic stimulation to the vestibular system. The NEURVESTA treatment protocol only requires three 20-minute sessions per week for 6 weeks to deliver long-lasting neuroplastic restoration of balance and mobility, and dramatic reductions in fall risk, and has been shown to be effective in study populations from 50 to 95 years of age.
Video Demonstration: